Identification
Indications
Traitement des patients atteints de carcinome hépatocellulaire. Traitement des patients atteints de carcinome à cellules rénales avancé après néphrectomie et prétraitement palliatif ou adjuvant par des cytokines (IL-2, IFN). Traitement des patients atteints du carcinome thyroïdien progressif, localement avancé ou métastatique, différencié, réfractaire à l'iode radioactif. Source : Compendium.ch - Date : 21 octobre 2025
Find an open pharmacy
On-call pharmacies near you
About NEXAVAR 200 MG
NEXAVAR 200 MG is marketed in Morocco by BAYER S.A and is among the pharmaceutical specialties referenced by the Ministry of Health.
For any question about the use, effects, or drug interactions of NEXAVAR 200 MG, consult your doctor or pharmacist. This information is provided for educational purposes and does not replace medical advice.
Frequently Asked Questions about NEXAVAR 200 MG
Answers to common questions from Moroccan patients about this drug.